other material
confidence high
sentiment neutral
materiality 0.40
Tonix doses first patient in Phase 2 OASIS trial of TNX-102 SL for acute stress reaction
Tonix Pharmaceuticals Holding Corp.
- Phase 2 OASIS trial evaluating TNX-102 SL in reducing severity of acute stress reaction and frequency of acute stress disorder.
- Trial sponsored by UNC Institute for Trauma Recovery with a $3 million grant from the U.S. Department of Defense.
- Plans to enroll ~180 motor vehicle collision survivors at U.S. emergency departments; randomized to TNX-102 SL 5.6 mg or placebo for two weeks.
- Topline results expected in the second half of 2026.